MONROVIA, Calif. , Sept. 25, 2018 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that company management will

- Dosed the First Patient in DUET-2, Phase 1 Clinical Trial of Lead Tumor Microenvironment (TME) Activator XmAb®20717 in Advanced Solid Tumors - - Expect to Announce Topline Data from Phase 2 Trial of XmAb®5871 in Systemic Lupus Erythematosus (SLE) and Initial Data from Phase 1 Trial of XmAb®14045

MONROVIA, Calif. , Aug. 1, 2018 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that company management will

MONROVIA, Calif. , July 30, 2018 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced that it will release second quarter

MONROVIA, Calif. , July 12, 2018 /PRNewswire/ --  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that the first patient has been

MONROVIA, Calif. , May 31, 2018 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that company management will

-- Introduced XmAb® IL15 Bispecific Antibody Platform and Presented Preclinical Data on XmAb®24306 at American Association for Cancer Research (AACR) Annual Meeting -- - Completed Public Offering, Raising $245.5M and Extending Cash Runway into 2023 - -- Expect to Initiate Phase 3 Trial of XmAb®5871

MONROVIA, Calif. , May 2, 2018 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat , Ph.D.,

MONROVIA, Calif. , April 30, 2018 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced that it will release first quarter

MONROVIA, Calif. , April 18, 2018 /PRNewswire/ -- Xencor , Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced preclinical data on XmAb24306, an